Daiichi Sankyo forecast to retain top spot in ADC market

7 August 2023

Increased activity and investment in the development of antibody-drug conjugates (ADCs) has been evident in the oncology market in the past two to three years.

A recent look at the marketed and pipeline drugs shows that Japan’s Daiichi Sankyo (TYO: 4568), the Pfizer (NYSE: PFE) target Seagen (Nasdaq: SGEN) and Swiss pharma giant Roche (ROG: SIX) are three of the most important players in this wave.

"The promise and potential of ADCs remain robust, and the market continues to recognize their value"Daiichi’s recent trial results suggest that the company will continue to remain dominant in the oncology ADC market, according to GlobalData, the data and analytics company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK